These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35491201)

  • 21. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Value Analysis of in-Stent Restenosis Within Three Years in Older Acute Coronary Syndrome Patients: A Two-Center Retrospective Study.
    Zhou J; Chai D; Dai Y; Wang A; Yan T; Lu S
    Clin Appl Thromb Hemost; 2022; 28():10760296221107888. PubMed ID: 35706375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.
    Nojima Y; Yasuoka Y; Kume K; Adachi H; Hattori S; Matsutera R; Kohama Y; Sasaki T
    Coron Artery Dis; 2014 Dec; 25(8):638-44. PubMed ID: 25076360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albumin to globulin ratio was associated with in-stent restenosis and revascularization events after percutaneous coronary intervention.
    Zhang R; Tao Z; Gong J; Ji Z; Yang M; Ma G; Li Y
    Clin Transl Sci; 2022 May; 15(5):1187-1195. PubMed ID: 35195938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention.
    Zheng JF; Guo TT; Tian Y; Wang Y; Hu XY; Chang Y; Qiu H; Dou KF; Tang YD; Yuan JQ; Wu YJ; Yan HB; Qiao SB; Xu B; Yang YJ; Gao RL
    Chin Med J (Engl); 2020 Nov; 133(22):2674-2681. PubMed ID: 33009028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.
    Cheng G; Chang FJ; Wang Y; You PH; Chen HC; Han WQ; Wang JW; Zhong NE; Min ZQ
    Med Sci Monit; 2019 Jan; 25():240-247. PubMed ID: 30617247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of M2BP in predicting in-stent restenosis in patients after coronary drug-eluting stent implantation.
    Yang L; Zhu H; Sun Y; Yan P; Song X; Xu F; Yuan H; Chen L
    Clin Cardiol; 2022 Mar; 45(3):308-314. PubMed ID: 35032135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of in-stent neointimal tissue components following drug-eluting stent implantation according to the phase of restenosis using a 40-MHz intravascular ultrasound imaging system.
    Araki T; Nakamura M; Sugi K
    J Cardiol; 2014 Dec; 64(6):423-9. PubMed ID: 24794755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravascular Ultrasound and Angiographic Predictors of In-Stent Restenosis of Chronic Total Occlusion Lesions.
    Kang J; Cho YS; Kim SW; Park JJ; Yoon YE; Oh IY; Yoon CH; Suh JW; Youn TJ; Chae IH; Choi DJ
    PLoS One; 2015; 10(10):e0140421. PubMed ID: 26465755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atherogenic Index of Plasma and the Risk of In-Stent Restenosis in Patients with Acute Coronary Syndrome beyond the Traditional Risk Factors.
    Zhu Y; Chen M; Liu K; Gao A; Kong X; Liu Y; Han H; Li H; Zhu H; Zhang J; Zhao Y
    J Atheroscler Thromb; 2022 Aug; 29(8):1226-1235. PubMed ID: 34497172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of anemia on in-stent restenosis after percutaneous coronary intervention.
    Hu H; Wang S; Tang G; Zhai C; Shen L
    BMC Cardiovasc Disord; 2021 Nov; 21(1):548. PubMed ID: 34798833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
    Zeng WP; Zhang R; Li R; Luo JF; Hu XF
    PLoS One; 2017; 12(1):e0170964. PubMed ID: 28129392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of peripheral blood eosinophil count in predicting in-stent restenosis in patients with stable angina pectoris undergoing drug eluting stenting.
    Hajizadeh R; Ghaffari S; Separham A; Shokouhi B; Kavandi H; Pourafkari L; Nader ND
    Rom J Intern Med; 2017 Dec; 55(4):229-236. PubMed ID: 28672766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.